PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Jennifer Wargo, MD, MMSc - The Path Forward for Immunotherapy in Resectable Melanoma: Principles and Perspectives on Using Immune-Based Adjuvant and Neoadjuvant Therapy
Go online to PeerView.com/KNX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading melanoma experts discuss the role of immunotherapy as a standard adjuvant option in stage III/IV—and potentially stage II—disease and the potential of neoadjuvant checkpoint blockade in certain resectable settings (eg, macroscopic stage III disease). Real-world examples of immunotherapy treatment in resectable disease and the foundational and emerging science that continues to inform surgical oncology care are also presented. Upon completion of this activity, participants should be better able to: Cite current evidence and guideline recommendations for the use of immunotherapy in resectable stage III/IV melanoma, Describe efficacy and safety data surrounding the use of immunotherapy as adjuvant or neoadjuvant therapy in resectable melanoma, including in stage II or stage III macroscopic disease, respectively, Integrate adjuvant or neoadjuvant immunotherapy into the management of patients with resectable melanoma, including those with BRAF-positive or BRAF-negative disease, Manage immune-related adverse events in patients with melanoma receiving immunotherapy in conjunction with surgery.